Abstract

Venous thromboembolism (VTE) poses a significant concern for cancer patients, contributing to increased morbidity and mortality rates. This review explores the epidemiology, risk factors, and therapeutic strategies pertinent to cancer-associated thrombosis (CAT). It underscores the critical role of risk assessment models, the efficacy of anticoagulant therapies, and the necessity for personalized treatment approaches to optimally manage CAT. Additionally, the review examines the specific characteristics of CAT patients in Türkiye, emphasizing the importance of vigilant monitoring and management to reduce VTE risks in oncology patients. The insights presented aim to refine clinical practices and enhance patient outcomes by addressing existing gaps and proposing effective solutions for improved CAT management.

Key words: Venous thromboembolism, neoplasms, anticoagulants, direct-acting oral anticoagulants, low molecular weight heparin